H7
H7T1.F HUTCHMED (China) Limited
- Market cap
- EUR 2.24B
- P/E
- 143.3x
- P/B
- 2.05x
- ROE
- 36.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is H7T1.F undervalued?
Graham numberThe Graham number of HUTCHMED (China) Limited cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HUTCHMED (China) Limited fundamental analysis
No fundamental analysis for HUTCHMED (China) Limited yet.
HUTCHMED (China) Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), …
Full company profileHUTCHMED (China) Limited financial statements
HUTCHMED (China) Limited annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 216M | 241M | 214M | 205M | 228M | 356M | 426M | 838M | 630M | 549M |
| Gross Profit | 59.8M | 65.4M | 70.2M | 44.7M | 39.5M | 97.9M | 115M | 454M | 281M | 212M |
| Operating Income | -46.7M | -53.4M | -92.6M | -145M | -197M | -328M | -408M | 21.5M | -40.6M | -35.7M |
| EBITDA | - | -49.5M | -82.1M | -135M | -183M | -208M | -401M | 67.3M | 14.1M | 515M |
| Net Income | 11.7M | -26.7M | -74.8M | -106M | -126M | -195M | -361M | 101M | 37.7M | 457M |
| EPS | - | -0.04 | -0.11 | -0.16 | -0.17 | -0.23 | -0.42 | 0.12 | 0.04 | 0.53 |
| Balance Sheet | ||||||||||
| Total Assets | 342M | 598M | 532M | 465M | 724M | 1.37B | 1.03B | 1.28B | 1.27B | 1.75B |
| Total Liabilities | 138M | 113M | 120M | 152M | 205M | 333M | 393M | 536M | 502M | 502M |
| Shareholders' Equity | 184M | 462M | 389M | 288M | 484M | 987M | 610M | 731M | 760M | 1.24B |
| Cash & Short-term Investments | 79.4M | 85.3M | 86.0M | 121M | 236M | 378M | 313M | 284M | 154M | 71.3M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -9.57M | -8.94M | -32.8M | -80.9M | -62.1M | -204M | -269M | 219M | 497K | -64.7M |
| Capital Expenditure | 4.33M | 5.02M | 6.36M | 8.57M | 7.95M | 16.4M | 36.7M | 32.6M | 17.9M | 24.1M |
| Free Cash Flow | - | -14.0M | -39.2M | -89.5M | -81.6M | -221M | -305M | 187M | -17.4M | -88.8M |
| Ratios | ||||||||||
| ROE | 6.3% | -5.8% | -19.2% | -36.8% | -26.0% | -19.7% | -59.1% | 13.8% | 5.0% | 36.9% |
| ROA | 3.4% | -4.5% | -14.1% | -22.8% | -17.4% | -14.2% | -35.1% | 7.9% | 3.0% | 26.1% |
| Net Profit Margin | 5.4% | -11.1% | -34.9% | -51.7% | -55.2% | -54.7% | -84.6% | 12.0% | 6.0% | 83.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
HUTCHMED (China) Limited dividends
HUTCHMED (China) Limited has not paid dividends in the last 10 fiscal years.
Who owns HUTCHMED (China) Limited
- Insiders 0.05%
- Institutions 2.60%
- Public & others 97.35%
- Shares outstanding 174M
- Free float 106M
HUTCHMED (China) Limited company profile
- Company name
- HUTCHMED (China) Limited
- Ticker
- H7T1.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,790
- Fiscal year end
- December
- Address
- Cheung Kong Center, Hong Kong, Hong Kong
- Phone
- 852 2121 8200
- Website
- hutch-med.com
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
HUTCHMED (China) Limited management
10- Mr. Chig Fung Cheng BEc, CAActing CEO, CFO & Executive Director · born 1967
- Dr. Wei-Guo Su B.Sc., Ph.D.CEO, Chief Scientific Officer & Executive Director (Leave of Absence) · born 1959
- Ms. Yiling CuiExecutive VP & Head of Operations
- Dr. Xinhui Hu Ph.D.Executive Vice President & Chief Technical Officer · born 1973
- Mr. David NgHead of Investor Relations & Capital Strategies
- Mr. Charles George Rupert NixonGroup General Counsel · born 1970
- Mr. Kin Hung Lee M.B.A.Senior Vice President of Corporate Management & Communications · born 1977
- Ms. Selina ZhangSenior Vice President of Global Human Resources
- Dr. Qingmei Wang Ph.D.Executive Vice President of Business Development & Strategic Alliances · born 1963
- Dr. Thomas FuSenior Vice President of Global Quality